International
The Morning Science

What science found today

‹
 

Launch

FDA OKs Drug Linked to Longer Survival in Fatal Genetic Disorder

MedPage Today ·

FDA OKs Drug Linked to Longer Survival in Fatal Genetic Disorder

The Brief

  • The FDA approved adrabetadex (Lembaz) injection on Tuesday for patients with infantile-onset Niemann-Pick disease type C (NPC).
  • NPC is described as a rare and fatal genetic disorder.
  • The approval is indicated for adults and children weighing at least 15 lb; the source snippet is truncated before the full indication.

Why it matters

This is the first approval of a treatment for infantile-onset NPC, a rare fatal disorder, and the reported link to longer survival could matter for clinicians and families managing the disease.

Who’s affected

  • clinicians treating rare genetic disorders
  • patients and families affected by Niemann-Pick disease type C

(MedPage Today) -- The FDA approved adrabetadex (Lembaz) injection on Tuesday for patients with infantile-onset Niemann-Pick disease type C (NPC), a rare and fatal genetic disorder. Indicated for adults and children weighing at least 15 lb whose...

Timeline

  1. FDA approves adrabetadex (Lembaz) injection for infantile-onset Niemann-Pick disease type C

  2. MedPageToday.com - medical news for physicians

    FDA OKs Drug Linked to Longer Survival in Fatal Genetic Disorder

How do you feel about this?

0 Comments

    FDA OKs Drug Linked to Longer Survival in Fatal Genetic Disorder – The Morning Science